# Anifrolumab Early Access Program

> **NCT04750057** · — · NO_LONGER_AVAILABLE · sponsor: **AstraZeneca**

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Anifrolumab

## Key facts

- **NCT ID:** NCT04750057
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04750057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04750057, "Anifrolumab Early Access Program". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04750057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*